MedTrace Logo

Efficacy of Bifidobacterium Longum 35624 on the Quality of Life of IBS Patients With Different Symptom Severity

NCT04662502 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 220

Last updated 2021-03-12

No results posted yet for this study

Summary

The main objective of this observatory is to evaluate the effect of Bifidobacterium longum 35624 on the quality of life of IBS patients having different subtypes of transit pattern and different level of symptom severity

Conditions

  • Irritable Bowel Syndrome

Interventions

DIETARY_SUPPLEMENT

Bifidobacterium longum 35624

Bifidobacterium longum 35624, 1 x 10\^9 CFU/capsule, 1 capsule/day over 1 month

Sponsors & Collaborators

  • Biocodex

    lead INDUSTRY

Principal Investigators

  • Gyasi K Johnson, PhD · Biocodex

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-22
Primary Completion
2020-01-29
Completion
2020-06-26

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04662502 on ClinicalTrials.gov